PULM Pulmatrix (PULM) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001574235
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
5
13F, latest reported quarter
PULM filings, in plain words
Read the full summary
The latest 5% ownership filing is a 13D by RCM Eos PIPE HOLDINGS, LLC, filed 2026-04-22, for 10.0% of the class. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Pulmatrix insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for Pulmatrix, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
no insider purchases or sales on record
0 transactions on record
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
5 funds bought in last quarter
below 95% of Pharma & Biotech
Revenue
+7.0% year over year
more than 56% of Pharma & Biotech
Margin
-66.1% net margin
below 53% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
1.2% of the float short (float per yahoo 2026-10-27) · 2.9 days to cover · settled 2026-10-15
below 71% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch PULM
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-70.3%12M
13D/G stake
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns PULM: institutional holders (13F)
13F holdings, latest reported quarter
122,698 sh
$208.6K
54,899 sh
$93.3K
33,299 sh
$56.6K
32,294 sh
$54.9K
31,285 sh
$53.2K
Congress trades in PULM
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
13D: intends to influence · 13G: passive
RCM Eos PIPE HOLDINGS, LLC
Activist 13D · 2026-04-22
9.99%
Slawin Kevin M.
Activist 13D · 2026-04-22
9.99%
Rapha Capital Management, LLC
Activist 13D · 2026-04-22
9.99%
PULM planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
PULM mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Fidelity Extended Market Index Fund
$32.0K position · as of 2026-05-31
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$54.9K position · as of 2026-06-30
0.0%
Fidelity Nasdaq Composite Index Fund
$6.4K position · as of 2026-05-31
0.0%
Fidelity Series Total Market Index Fund
$7.3K position · as of 2026-05-31
0.0%
Fidelity Total Market Index Fund
$6.2K position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
1 registered trials, 0 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
1
Phase 2
0 active
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 5 funds added last quarter. Each figure is a federal filing, dated the day it went public.
PULM financials
Revenue growth
+7.0%
XBRL, annual
Net margin
-66.1%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$7.8M
four quarters, 2024-01-01 to 2024-12-31
Revenue, TTM PULM
| FY Dec 2025 | $7.8M |
| FY Dec 2024 | $7.8M |
| FY Dec 2023 | $7.3M |
| FY Dec 2022 | $6.1M |
| FY Dec 2021 | $5.2M |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | $3.0K |
| Sep 2024 | $366.0K |
At each fiscal year end
Single quarter
Net margin, TTM
-51.4%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM PULM
| FY Dec 2025 | -66.1% |
| FY Dec 2024 | -122.5% |
| FY Dec 2023 | -193.5% |
| FY Dec 2022 | -310.3% |
| FY Dec 2021 | -390.2% |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | -706.8% |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$4.3M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM PULM
| FY Dec 2025 | -$5.8M |
| FY Dec 2024 | -$11.1M |
| FY Dec 2023 | n/a |
| FY Dec 2022 | -$19.4M |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | -$1.3M |
| Sep 2024 | -$3.1M |
At each fiscal year end
Single quarter
Debt to equity
0.71x
long-term 2017-06-30 (109 months older than the period end) plus current 2018-12-31 (91 months older than the period end); equity 2026-06-30
Debt to equity PULM
| FY Dec 2025 | 0.47x |
| FY Dec 2024 | 0.20x |
| FY Dec 2023 | 0.10x |
| FY Dec 2022 | 0.06x |
| FY Dec 2021 | 0.04x |
| Jun 2026 | 0.71x |
| Mar 2026 | 0.50x |
| Dec 2025 | 0.47x |
| Sep 2025 | 0.38x |
| Jun 2025 | 0.32x |
| Mar 2025 | 0.25x |
| Dec 2024 | 0.20x |
| Sep 2024 | 0.17x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-2.17x
TTM operating cash flow over long-term 2017-06-30 (109 months older than the period end) plus current 2018-12-31 (91 months older than the period end)
Cash flow to debt PULM
| FY Dec 2025 | -3.01x |
| FY Dec 2024 | -5.94x |
| FY Dec 2023 | -8.86x |
| FY Dec 2022 | -10.73x |
| FY Dec 2021 | -10.94x |
| Jun 2026 | -2.17x |
| Mar 2026 | -2.60x |
| Dec 2025 | -3.01x |
| Sep 2025 | -3.32x |
| Jun 2025 | -4.44x |
| Mar 2025 | -5.44x |
| Dec 2024 | -5.94x |
| Sep 2024 | -6.36x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-98.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity PULM
| FY Dec 2025 | -80.9% |
| FY Dec 2024 | -71.0% |
| FY Dec 2023 | -57.5% |
| FY Dec 2022 | -48.0% |
| FY Dec 2021 | -57.2% |
| Jun 2026 | -98.3% |
| Mar 2026 | -84.3% |
| Dec 2025 | -80.9% |
| Sep 2025 | -79.5% |
| Jun 2025 | -83.9% |
| Mar 2025 | -93.2% |
| Dec 2024 | -71.0% |
| Sep 2024 | -62.7% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-85.4%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets PULM
| FY Dec 2025 | -73.3% |
| FY Dec 2024 | -43.5% |
| FY Dec 2023 | -37.7% |
| FY Dec 2022 | -37.8% |
| FY Dec 2021 | -41.6% |
| Jun 2026 | -85.4% |
| Mar 2026 | -72.1% |
| Dec 2025 | -73.3% |
| Sep 2025 | -75.4% |
| Jun 2025 | -72.3% |
| Mar 2025 | -63.4% |
| Dec 2024 | -43.5% |
| Sep 2024 | -40.0% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on invested capital PULM
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-100.8%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed PULM
| FY Dec 2025 | -80.6% |
| FY Dec 2024 | -50.0% |
| FY Dec 2023 | -44.7% |
| FY Dec 2022 | -42.0% |
| FY Dec 2021 | -47.9% |
| Jun 2026 | -100.8% |
| Mar 2026 | -85.9% |
| Dec 2025 | -80.6% |
| Sep 2025 | -79.4% |
| Jun 2025 | -84.6% |
| Mar 2025 | -71.9% |
| Dec 2024 | -50.0% |
| Sep 2024 | -46.4% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing PULM
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$4.9M
market value at close 2026-10-26 on 2026-08-13 shares, plus long-term 2017-06-30 (109 months older than the period end) plus current 2018-12-31 (91 months older than the period end), minus cash 2026-06-30
Enterprise value PULM
| FY Dec 2025 | $5.9M |
| FY Dec 2024 | $17.8M |
| FY Dec 2023 | -$10.6M |
| FY Dec 2022 | -$19.7M |
| FY Dec 2021 | $440.7M |
| Jun 2026 | $5.8M |
| Mar 2026 | $3.2M |
| Dec 2025 | $5.9M |
| Sep 2025 | $14.8M |
| Jun 2025 | $21.2M |
| Mar 2025 | $18.4M |
| Dec 2024 | $17.8M |
| Sep 2024 | -$1.2M |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-81.9%
TTM free cash flow over market value at close 2026-10-26
FCF yield PULM
| FY Dec 2025 | -71.6% |
| FY Dec 2024 | -43.6% |
| FY Dec 2023 | n/a |
| FY Dec 2022 | -137.7% |
| FY Dec 2021 | n/a |
| Jun 2026 | -69.4% |
| Mar 2026 | -107.9% |
| Dec 2025 | -71.6% |
| Sep 2025 | -36.0% |
| Jun 2025 | -33.4% |
| Mar 2025 | -42.0% |
| Dec 2024 | -43.6% |
| Sep 2024 | -155.7% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing PULM
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | n/a | $7.8M | $7.3M | $6.1M |
| Operating income | -$5.2M | -$9.8M | -$14.7M | -$18.9M |
| Net income | -$5.2M | -$9.6M | -$14.1M | -$18.8M |
| EPS (diluted) | -1.41 | -2.62 | -3.87 | n/a |
| Operating cash flow | -$5.4M | -$10.7M | -$16.0M | -$19.4M |
| Cash | $4.1M | $9.5M | $19.2M | $35.6M |
SEC XBRL, fiscal years, as known on 2026-10-28
PULM Stock Sonar score 5/7 axes
Find similar shapesComparePULM ranks highest on risk and compliance (83rd percentile) and growth (56th), and lowest on institutional and government (5th), among Pharma & Biotech peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
